Winner of the Bionow Product of the Year Award
IQoro has been awarded the prestigious Product of the Year award at the Bionow Awards held in Manchester on 7 March 2024. IQoro was the only foreign nominated entry to win the award, which according to the jury stood out for its effectiveness and ability to replace drugs and surgery.
Read moreSwedish innovation recognised in the UK- offsets the need for reflux medication and surgery
IQoro is a neuromuscular treatment and product for reflux and swallowing difficulties, which can offset the need for medication and surgery according to National Health Service innovation organisations in the UK. The Swedish innovation IQoro has been awarded the prestigious “Product of the Year” award at the Bionow Awards. The Bionow Awards is one of […]
Read moreIQoro shortlisted for Bionow Product of the Year Award
We are very proud to tell you that IQoro has been shortlisted in the category “Product of the Year” at the prestigious Bionow Awards that will be held in Manchester on March 7, 2024. The event is a highlight of the life sciences calendar and celebrates the achievements of the sector, showcasing the very best […]
Read moreIQoro on prescription
IQoro is available on prescription on the NHS, but far from all healthcare professionals have yet heard of the treatment. On this page, you’ll find a document that you can bring to your healthcare contact when you want to bring up IQoro as a potential treatment option. How to get IQoro on prescription IQoro is […]
Read moreMYoroface named one of the fastest growing companies in Europe
MYoroface, the Swedish healthtech company behind the IQoro, has been named one of the fastest growing companies in Europe. The award comes from the annual FT 1000 report developed by The Financial Times, which ranks European companies that have achieved the highest growth in recent years. In the UK, around 13 million people suffer from […]
Read moreIQoro achieves prescription status in the UK
From 1st May 2022 IQoro is listed as a device that a GP can prescribe in the UK. The GP’s will do this where they judge that IQoro is a suitable treatment for their patient’s condition.
Read moreInternational Reflux Day highlights a serious health problem
More than 20% of the world’s population suffer from reflux and endure symptoms like heartburn, acid reflux and thick phlegm. In many cases, so severely that it is difficult to eat normally – or even to lie down and sleep. To draw attention to this growing, global problem, International Reflux Day has been instituted on […]
Read moreA tiny piece of plastic literally saved my relationship!
I’m sure IQoro will be a part of my health routine for the rest of my life.
Swedish MedTech company MYoroface expands – innovative medical treatment for reflux now launched across the entire Nordic region
MYoroface is the Swedish MedTech company behind the unique innovation IQoro which treats the underlying cause of acid reflux, heartburn and more. IQoro has now been launched across all Nordic markets. Through a farsighted long-term global expansion strategy, the company wants to eventually address the fifth of the world’s population that suffer from acid reflux. […]
Read moreIQoro meets the new, more rigorous demands for the CE mark
A CE Mark is needed in order to introduce a MedTech product into the EU and currently the UK markets. Starting from 26th May 2021 the new MDR regulations 2017/745 will apply. These set higher demands on suppliers, but what will they mean for consumers? A summary of the new MDR regulations How has MYoroface […]
Read moreNew neuromuscular treatment for hiatus hernia shortens intervention times for Healthcare Professionals and patients
Swedish Associate Professors Thomas Franzén and Mary Hägg have written a book chapter for IntechOpen, the world’s leading publisher of Open Access books. The conclusions are that reflux is most commonly caused by Hiatus hernia and that this can be treated successfully with neuromuscular training. The treatment also shortens intervention times for Healthcare Professionals as […]
Read moreIQoro referenced in NICE pathway for treatment of reflux diseases in the NHS
In the UK, the National Health Service (NHS) is advised by, amongst others, The National Institute for Health and Care Excellence (NICE). NICE provide national guidance and advice to improve health and social care. Now, they have updated their guidelines on two pathways that recommend treatments for reflux diseases. Both highlight IQoro as a treatment: – […]
Read more